Pharmanormal activities

When Monique Levy, one of the most-level-headed analysts in the pharma industry, calls attention to a mysterious phenomenon, you listen.

Editor's Desk: And the researchers go wild

Apple's ResearchKit could accelerate the pace at which industry approaches start-ups building products in the patient-facing part of health tech

Editor's Desk—Pill+: Now I'm a Believer

If you look at this as simply a tool to drive your brand, you've missed the point

Editor's Desk: Trials and innovations

How should pharma organize around adjacencies to therapeutics?

Editor's Desk: Whither the fast followers?

Will DIY and the mHealth movement be the catalysts driving change?

Disruption on display

As these 40 standouts show, the industry is ready to move forward

Adherence is in the behavior

There needs to be a greater effort put into the issue of adherence. What can academia, providers, pharma and payers do to address this pressing need?

Marketing to Millennials

Gen Y wants companies to stand for "Important missions and values"

Down... but not out

Satisfaction levels among pharma-based respondents fell, but didn't exactly tank

Live, listen and learn

Companies are realizing that they need to be more attuned to their audience

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.